{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:14:56Z","timestamp":1788189296461,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,31]]},"DOI":"10.7759\/cureus.85123","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:30:37Z","timestamp":1748687437000},"source":"Crossref","is-referenced-by-count":5,"title":["Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use"],"prefix":"10.7759","author":[{"given":"Sara","family":"Humaida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamar","family":"Manzalji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naheel","family":"Seyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolwa","family":"Al-Masalmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin J","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, et al.. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023, 46:384-90. 10.2337\/dc22-1148","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu W","year":"2022","unstructured":"Hu W, Song R, Cheng R, et al.. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022, 13:927859. 10.3389\/fendo.2022.927859","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2196\/55976","article-title":"Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the Food and Drug Administration Adverse Event Reporting System: retrospective analysis","volume":"5","author":"Makunts T","year":"2024","unstructured":"Makunts T, Joulfayan H, Abagyan R. Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the Food and Drug Administration Adverse Event Reporting System: retrospective analysis. JMIRx Med. 2024, 5:e55976. 10.2196\/55976","journal-title":"JMIRx Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce EN","year":"2003","unstructured":"Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003, 348:2646-55. 10.1056\/NEJMra021194","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn Chair RS","year":"2011","unstructured":"Bahn Chair RS, Burch HB, Cooper DS, et al.. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011, 21:593-646. 10.1089\/thy.2010.0417","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker DJ","year":"2010","unstructured":"Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010, 33:428-33. 10.2337\/dc09-1499","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.24018\/ejmed.2023.5.3.1743","article-title":"Semaglutide-induced subclinical hypothyroidism: a case report","volume":"5","author":"Mazokopakis EE","year":"2023","unstructured":"Mazokopakis EE. Semaglutide-induced subclinical hypothyroidism: a case report. Eur J Med Health Sci. 2023, 5:8-9. 10.24018\/ejmed.2023.5.3.1743","journal-title":"Eur J Med Health Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370785-dual-glucagon-like-peptide-1-glp-1-and-glucose-dependent-insulinotropic-polypeptide-gip-receptor-agonist-associated-thyroiditis-a-case-report-of-thyroid-dysfunction-following-tirzepatide-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:30:37Z","timestamp":1748687437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370785-dual-glucagon-like-peptide-1-glp-1-and-glucose-dependent-insulinotropic-polypeptide-gip-receptor-agonist-associated-thyroiditis-a-case-report-of-thyroid-dysfunction-following-tirzepatide-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.85123","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,31]]}}}